|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isobe Y, Nashimoto A, Akazawa K, Oda I,
Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y and
Kaminishi M: Gastric cancer treatment in Japan: 2008 nnual report
of the JGCA nationwide registry. Gastric Cancer. 14:301–316. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sadeghi B, Arvieux C, Glehen O, Beaujard
AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL,
Faure JL, et al: Peritoneal carcinomatosis from non-gynecologic
malignancies: Results of the EVOCAPE 1 multicentric prospective
study. Cancer. 88:358–363. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McQuellon RP, Loggie BW, Fleming RA,
Russell GB, Lehman AB and Rambo TD: Quality of life after
intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal
carcinomatosis. Eur J Surg Oncol. 27:65–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garofalo A, Valle M, Garcia J and
Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic
chemotherapy for palliation of debilitating malignant ascites. Eur
J Surg Oncol. 32:682–685. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glockzin G, Ghali N, Lang SA, Agha A,
Schlitt HJ and Piso P: Peritoneal carcinomatosis. Surgical
treatment, including hyperthermal intraperitoneal chemotherapy.
Chirurg. 78(1100): 1102–1106, 1108-1110. 2007.(In German).
|
|
10
|
Roth AD, Fazio N, Stupp R, Falk S,
Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R,
et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and
cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic
treatment for advanced gastric carcinoma: A randomized phase II
trial of the Swiss Group for Clinical Cancer Research. J Clin
Oncol. 25:3217–3223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dedrick RL, Myers CE, Bungay PM and DeVita
VT Jr: Pharmacokinetic rationale for peritoneal drug administration
in the treatment of ovarian cancer. Cancer Treat Rep. 62:1–11.
1978.PubMed/NCBI
|
|
12
|
Markman M: Intraperitoneal antineoplastic
drug delivery: Rationale and results. Lancet Oncol. 4:277–283.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Detroz B, Laurent S, Honoré P, Blaffart F,
Limet R and Meurisse M: Rationale for hyperthermic intraperitoneal
chemotherapy (HIPEC) in the treatment or prevention of peritoneal
carcinomatosis. Acta Chir Belg. 104:377–383. 2004.PubMed/NCBI
|
|
14
|
González-Moreno S, González-Bayón LA and
Ortega-Pérez G: Hyperthermic intraperitoneal chemotherapy:
Rationale and technique. World J Gastrointest Oncol. 2:68–75. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van der Speeten K, Stuart OA and
Sugarbaker PH: Using pharmacologic data to plan clinical treatments
for patients with peritoneal surface malignancy. Curr Drug Discov
Technol. 6:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan TD, Cao CQ and Munkholm-Larsen S: A
pharmacological review on intraperitoneal chemotherapy for
peritoneal malignancy. World J Gastrointest Oncol. 2:109–116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tozzoli R, Basso SM, D'Aurizio F, Metus P
and Lumachi F: Evaluation of predictive value of pleural CEA in
patients with pleural effusions and histological findings: A
prospective study and literature review. Clin Biochem.
49:1227–1231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yonemura Y, Endou Y, Sasaki T, Hirano M,
Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M and Li Y:
Surgical treatment for peritoneal carcinomatosis from gastric
cancer. Eur J Surg Oncol. 36:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan TD, Black D, Savady R and Sugarbaker
PH: Systematic review on the efficacy of cytoreductive surgery
combined with perioperative intraperitoneal chemotherapy for
peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol.
24:4011–4019. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chua TC, Robertson G, Liauw W, Farrell R,
Yan TD and Morris DL: Intraoperative hyperthermic intraperitoneal
chemotherapy after cytoreductive surgery in ovarian cancer
peritoneal carcinomatosis: Systematic review of current results. J
Cancer Res Clin Oncol. 135:1637–1645. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glehen O, Gilly FN, Arvieux C, Cotte E,
Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F and Elias
D: Association Française de Chirurgie: Peritoneal carcinomatosis
from gastric cancer: A multi-institutional study of 159 patients
treated by cytoreductive surgery combined with perioperative
intraperitoneal chemotherapy. Ann Surg Oncol. 17:2370–2377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JY and Bae HS: A controlled clinical
study of serosa-invasive gastric carcinoma patients who underwent
surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Gastric Cancer. 4:27–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Glehen O, Schreiber V, Cotte E,
Sayag-Beaujard AC, Osinsky D, Freyer G, François Y, Vignal J and
Gilly FN: Cytoreductive surgery and intraperitoneal
chemohyperthermia for peritoneal carcinomatosis arising from
gastric cancer. Arch Surg. 139:20–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 Study
Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scaringi S, Kianmanesh R, Sabate JM,
Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y and
Msika S: Advanced gastric cancer with or without peritoneal
carcinomatosis treated with hyperthermic intraperitoneal
chemotherapy: A single western center experience. Eur J Surg Oncol.
34:1246–1252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yonemura Y, Endou Y, Shinbo M, Sasaki T,
Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, et
al: Safety and efficacy of bidirectional chemotherapy for treatment
of patients with peritoneal dissemination from gastric cancer:
Selection for cytoreductive surgery. J Surg Oncol. 100:311–316.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Los G, van Vugt MJ and Pinedo HM: Response
of peritoneal solid tumours after intraperitoneal chemohyperthermia
treatment with cisplatin or carboplatin. Br J Cancer. 69:235–241.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yonemura Y: Hyperthermo-chemotherapy for
treatment of peritoneal disseminationPeritoneal Dissemination.
Yonemura Y: Kanazawa: Maeda Shoten; pp. 237–260. 1998
|
|
30
|
Fushida S, Kinoshita J, Kaji M, Hirono Y,
Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y and Fujimura T: Society
for Study of Peritoneal Carcinomatosis in Gastric Cancer: Phase
I/II study of intraperitoneal docetaxel plus S-1 for the gastric
cancer patients with peritoneal carcinomatosis. Cancer Chemother
Pharmacol. 71:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Link KH, Roitman M, Holtappels M,
Runnebaum I, Urbanzyk H, Leder G and Staib L: Intraperitoneal
chemotherapy with mitoxantrone in malignant ascites. Surg Oncol
Clin N Am. 12:865–872, xvi-xvii. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bando E, Yonemura Y, Takeshita Y,
Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T,
Nishimura G and Miwa K: Intraoperative lavage for cytological
examination in 1,297 patients with gastric carcinoma. Am J Surg.
178:256–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sugarbaker PH and Yonemura Y: Clinical
pathway for the management of resectable gastric cancer with
peritoneal seeding: Best palliation with a ray of hope for cure.
Oncology. 58:96–107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chu DZ, Lang NP, Thompson C, Osteen PK and
Westbrook KC: Peritoneal carcinomatosis in nongynecologic
malignancy. A prospective study of prognostic factors. Cancer.
63:364–367. 1989. View Article : Google Scholar : PubMed/NCBI
|
